Evaxion A (EVAX) Assets Average (2021 - 2026)
Evaxion A's (EVAX) quarterly Assets Average came in at $26.0 million in Q1 2026, up 37.98% YoY from $18.9 million in Q1 2025, and down 10.48% on a QoQ basis from $29.1 million in Q4 2025.
Evaxion A (EVAX) Assets Average (2021 - 2026) Analysis & Trends
Evaxion A (EVAX) has 6 years of Assets Average data on file, last reported at $26.0 million in Q1 2026.
- Quarterly Assets Average rose 37.98% year-over-year to $26.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.0 million (up 37.98% YoY) and the FY2025 annual result came in at $20.4 million, up 61.16% from the prior year.
- Assets Average slipped to $26.0 million in Q1 2026, from $29.1 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $40.6 million in Q1 2022 to a low of $6.5 million in Q1 2024.
- A 5-year average of $22.5 million and a median of $23.8 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average tumbled 69.63% — and 2025, when it surged 212.63%.
- Tracing EVAX's Assets Average over 5 years: stood at $24.7 million in 2022, then slumped by 49.81% to $12.4 million in 2023, then tumbled by 38.57% to $7.6 million in 2024, then soared by 281.19% to $29.1 million in 2025, then retreated by 10.48% to $26.0 million in 2026.
- The last three Assets Average figures came in at $26.0 million (Q1 2026), $29.1 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | 26.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.03 Mn |
| Dec 31, 2025 | 29.07 Mn |
| Sep 30, 2025 | 26.09 Mn |
| Jun 30, 2025 | 23.84 Mn |
| Mar 31, 2025 | 18.86 Mn |
| Jun 30, 2024 | 7.63 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 12.42 Mn |
| Sep 30, 2023 | 14.35 Mn |
| Jun 30, 2023 | 18.62 Mn |
| Mar 31, 2023 | 21.26 Mn |
| Dec 31, 2022 | 24.74 Mn |
| Sep 30, 2022 | 30.73 Mn |
| Jun 30, 2022 | 37.54 Mn |
| Mar 31, 2022 | 40.62 Mn |
| Dec 31, 2021 | 32.14 Mn |
| Sep 30, 2021 | 25.89 Mn |
| Jun 30, 2021 | 31.29 Mn |
| Mar 31, 2021 | 23.44 Mn |